Tafluprost

Patient with risk factors for or active intraocular inflammation (e.g. iritis, uveitis), aphakia, pseudophakia with torn posterior lens capsule or anterior chamber lenses; risk factors for cystoid macular oedema; angle-closure glaucoma, narrow-angle glaucoma, congenital glaucoma, neovascular glaucoma; asthma. Renal and hepatic impairment. Pregnancy and lactation.

Significant: Increased brown pigmentation of the iris and eyelid skin; eyelashes and vellus hair changes (e.g. misdirected growth of eyelashes, increased in number, length, color, thickness, and shape); macular oedema (including cystoid macular oedema); exacerbation of intraocular inflammation.
Eye disorders: Conjunctival or ocular hyperaemia, eye irritation or stinging, foreign body sensation, eye pruritus, eye pain, dry eye, cataract, blurred vision, eyelid erythema, superficial punctate keratitis, increased lacrimation, reduced visual acuity, photophobia.
Nervous system disorders: Headache.
Renal and urinary disorders: UTI.
Respiratory, thoracic and mediastinal disorders: Common cold, cough, exacerbation of asthma, dyspnoea.

Ophth: C

This drug may cause transient blurring of vision, if affected, do not drive or operate machinery. Remove contact lenses prior to administration and reinsert them after 15 minutes.

Monitor IOP. Regularly assess patients who develop noticeably increased iris pigmentation.

Description:
Mechanism of Action: Tafluprost, a tafluprost acid prodrug, is a fluorinated analogue of prostaglandin F_2α and a highly potent and selective prostanoid agonist. Its exact mechanism of action has not been fully elucidated; however, it appears to lower intraocular pressure (IOP) by increasing the aqueous humour outflow through the uveoscleral pathway.
Onset: 2-4 hours (IOP reduction).
Duration: ≥24 hours.
Pharmacokinetics:
Absorption: Absorbed through the cornea. Time to peak plasma concentration: Approx 10 minutes.
Metabolism: Rapidly hydrolysed by corneal esterases into tafluprost acid (biologically active metabolite); tafluprost acid is further metabolised via fatty acid β-oxidation and phase II conjugation.

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 9868491, Tafluprost. https://pubchem.ncbi.nlm.nih.gov/compound/Tafluprost. Accessed Oct. 28, 2024.

Unopened bottle/foil pouch: Store between 2-8°C. Do not freeze. Protect from light. Opened bottle/foil pouch: Store between 20-25°C. Protect from light and moisture.

Thuốc trị tăng nhãn áp

S01EE05 - tafluprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.

Anon. Tafluprost. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 04/09/2024.

Brayfield A, Cadart C (eds). Tafluprost. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/09/2024.

Joint Formulary Committee. Tafluprost. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/09/2024.

Saflutan 15 micrograms/mL Eye Drops, Solution (Santen Oy). MHRA. https://products.mhra.gov.uk. Accessed 04/09/2024.

Saflutan 15 micrograms/mL Eye Drops, Solution, in Single-dose Container (Santen Oy). MHRA. https://products.mhra.gov.uk. Accessed 04/09/2024.

Taflotan Ophthalmic Solution 0.0015% (Santen Pharma Malaysia Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 04/09/2024.

Taflotan-S Ophthalmic Solution 0.0015% (Santen Pharma Malaysia Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 04/09/2024.

Tafluprost. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 04/09/2024.

Zioptan Solution/Drops (Thea Pharma Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/09/2024.